New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
09:53 EDTZMH, SYK, JNJBiomet results positive for large reconstructive players, says Wells Fargo
After privately-held Biomet reported knee growth accelerated to 8% and hip growth declined slightly to 4% in its second quarter, Wells Fargo said the results are a positive sign for the reconstructive market. Wells added that it expects larger reconstructive industry companies, including Zimmer (ZMH), Stryker (SYK), and Johnson & Johnson (JNJ), to trade higher following Biomet's results.
News For ZMH;SYK;JNJ From The Last 14 Days
Check below for free stories on ZMH;SYK;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
08:39 EDTJNJOrganovo enters 3D bio-printed tissue agreement with J&J unit
Organovo (ONVO) announced that it has entered into an agreement with Janssen Research and Development, a pharmaceutical company of Johnson & Johnson (JNJ), to evaluate the use of 3D bio-printed tissue in a drug discovery setting, outside of the company’s work in 3D liver tissue for toxicity testing. Terms were not disclosed.
08:27 EDTZMHZimmer 'confident' Biomet merger transaction to be completed in 1Q15
Subscribe for More Information
08:25 EDTZMHZimmer sees FY14 gross margin ratio at 73%-74%
Expects FY14 SG&A to be unchanged, although it says there will be a seasonally higher ratio in Q3. Sees FY14 tax rate of 25.5%.
08:25 EDTZMHZimmer sees Q3 EPS $1.29-$1.31, consensus $1.37
Subscribe for More Information
08:19 EDTZMH, SYK, JNJLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
07:48 EDTZMHZimmer cuts FY14 EPS to $6.00-$6.10 from $6.00-$6.20, consensus $6.12
Subscribe for More Information
07:47 EDTZMHZimmer reports Q2 adjusted EPS $1.49, consensus $1.49
Reports Q2 revenue $1.18b, consensus $1.21B
July 23, 2014
13:36 EDTSYKIntuitive Surgical rises after Q2 EPS, revenue beat expectations
Subscribe for More Information
July 22, 2014
08:36 EDTSYKStryker appoints CEO Kevin Lobo as chairman
Subscribe for More Information
08:15 EDTZMHZimmer should be bought on any weakness from Q2 results, says RBC Capital
RBC Capital believes that consensus Q2 recon estimates for Zimmer may be "a bit optimistic," but the firm thinks that investors already partially anticipate a miss on that metric The firm recommends buying the stock on any weakness associated with Q2 results, as it thinks the company's valuation is favorable, given its growth outlook. RBC Capital keeps a $120 price target and Outperform rating on the shares.
July 21, 2014
18:40 EDTJNJOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
17:03 EDTJNJJohnson & Johnson announces $5B share repurchase program
Johnson & Johnson announced that its board has approved the repurchase of up to $5B of the company's common stock. The company had approximately 2.82B shares of common stock outstanding as of June 29.
17:01 EDTJNJJohnson & Johnson announces $5B share repurchase program
July 18, 2014
09:00 EDTSYKStryker price target raised to $92 from $87 at RW Baird
Baird raised its price target on Stryker to $92 from $87 citing valuation, organic sales growth, and solid risk/reward. The firm has an Outperform rating on the stock.
July 17, 2014
16:09 EDTSYKStryker sees Q3 adjusted EPS $1.12-$1.16 , consensus $1.16
"If foreign currency exchange rates hold near current levels, we do not expect the impact on third quarter or full year net sales to be significant," the company said.
16:08 EDTSYKStryker sees FY14 adjusted EPS $4.75-$4.80, consensus $4.80
Now projecting full year organic sales growth to be in the range of 5.0%-6.0%, consensus $9.61B.
16:07 EDTSYKStryker reports Q2 adjusted EPS $1.08, consensus $1.08
Subscribe for More Information
15:26 EDTSYKNotable companies reporting after market close
Subscribe for More Information
14:54 EDTJNJJohnson & Johnson weakness creates buying opportunity, says Argus
Subscribe for More Information
10:56 EDTJNJJohnson & Johnson reports 18% passive stake in Minerva
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use